Ticker >

Godavari Drugs share price

Godavari Drugs Ltd.

BSE: 530317 SECTOR: Pharmaceuticals & Drugs  15k   105   8

92.95
+0.75 (0.81%)
BSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 94.05

Today's Low

₹ 91.4

52 Week High

₹ 114

52 Week Low

₹ 73.31

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

70 Cr.

Enterprise Value

102.76 Cr.

No. of Shares

0.75 Cr.

P/E

16.59

P/B

1.93

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  48.21

CASH

3.08 Cr.

DEBT

35.85 Cr.

Promoter Holding

53.16 %

EPS (TTM)

₹  5.6

Sales Growth

-0.92%

ROE

12.01 %

ROCE

14.53%

Profit Growth

-27.82 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.92%
3 Year18.59%
5 Year19.89%

Profit Growth

1 Year-27.82%
3 Year23.69%
5 Year35.48%

ROE%

1 Year12.01%
3 Year16.64%
5 Year13.43%

ROCE %

1 Year14.53%
3 Year16.82%
5 Year14.88%

Debt/Equity

1.0727

Price to Cash Flow

5.3

Interest Cover Ratio

2.25651210755481

CFO/PAT (5 Yr. Avg.)

2.18280642604341

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 53.16 1.25
Sep 2023 53.16 1.25
Jun 2023 53.16 1.25
Mar 2023 53.12 0.12
Dec 2022 53.12 1.25
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 23.6856842212803% for the Past 3 years.
  • The company has shown a good revenue growth of 18.5947589191756% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 36.4531033951848 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.18280642604341.
  • The company has a high promoter holding of 53.16%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.67015346526263.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 39.16 37.37 35.42 39.54 43.11
Total Expenditure 36.89 34.69 33.17 36.48 39.59
Operating Profit 2.27 2.68 2.25 3.06 3.52
Other Income 0.3 0.16 0.45 0 0.05
Interest 1.1 1.03 1.11 1.3 1.28
Depreciation 0.51 0.5 0.47 0.49 0.5
Exceptional Items 0 0.23 0 0 -0.06
Profit Before Tax 0.96 1.55 1.12 1.27 1.74
Tax 0.29 0.21 0.31 0.42 0.52
Profit After Tax 0.67 1.33 0.81 0.86 1.22
Adjusted EPS (Rs) 0.89 1.77 1.08 1.14 1.62

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 83.54 95.7 122.67 161.11 159.62
Total Expenditure 78.06 89.66 112.83 149.82 149.7
Operating Profit 5.49 6.04 9.84 11.29 9.92
Other Income 0.24 0.33 0.41 0.28 0.66
Interest 2.9 2.91 3.32 2.85 3.93
Depreciation 1.09 1.16 1.22 1.7 1.94
Exceptional Items 0 0 0 0 0.23
Profit Before Tax 1.75 2.29 5.71 7.02 4.93
Tax 0.54 0.29 1.58 1.78 1.15
Net Profit 1.21 2 4.13 5.25 3.79
Adjusted EPS (Rs.) 1.6 2.66 5.48 6.97 5.03

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 7.53 7.53 7.53 7.53 7.53
Total Reserves 10.73 12.73 16.86 22.1 25.89
Borrowings 8.01 11.16 14.49 11.78 11.95
Other N/C liabilities 1.25 1.25 1.75 2.24 2.36
Current liabilities 46.22 51.25 50.51 57.76 73.71
Total Liabilities 73.74 83.92 91.14 101.41 121.43
Assets
Net Block 14.97 13.81 22.43 26.25 24.91
Capital WIP 2.05 8.93 0.76 0.49 9.08
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.23 0.35 0.33 0.23 0.34
Other N/C Assets 0 0 0 0.1 0.1
Current Assets 56.49 60.83 67.61 74.33 87.01
Total Assets 73.74 83.92 91.14 101.41 121.43
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 5.72 2.29 5.69 7.02 4.93
Adjustment -0.24 3.75 4.13 4.27 5.22
Changes in Assets & Liabilities -1.49 0.6 -6.92 1.72 4.22
Tax Paid -0.28 -0.39 -1.58 -1.78 -1.15
Operating Cash Flow 3.71 6.24 1.33 11.23 13.22
Investing Cash Flow -2.34 -6.68 -1.25 -4.97 -8.64
Financing Cash Flow -1.46 0.34 0.13 -5.62 -3.77
Net Cash Flow -0.09 -0.1 0.21 0.64 0.81

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 53.12 53.12 53.16 53.16 53.16
aksheit kakani 4.33 4.33 4.33 4.33 4.33
ghanshyam jaju 4.65 4.65 4.65 4.65 4.65
jaju ghanshyam huf 0.03 0.03 0.03 0.03 0.03
kamala jaju 12.08 12.08 12.08 12.08 12.08
kirti kumar jain 0.66 0.66 0.66 0.66 0.66
mohit jaju 5.84 5.84 7.10 7.10 7.10
mukund kakani 4.65 4.65 4.65 4.65 4.65
priyanka jaju 2.32 2.32 2.46 2.46 2.46
sushma kakani 14.08 14.08 15.34 15.34 15.34
tanushree kakani 1.86 1.86 1.86 1.86 1.86
prashant shrimal - 2.62 - - -
mangala shrimal 2.62 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 46.88 46.88 46.84 46.84 46.84
gautam chand jain 1.47 1.45 1.45 1.45 1.45
gopalakrishnan. v. 1.29 1.33 1.11 1.06 1.08
highcrestt global company... 2.66 2.66 2.66 2.66 2.66
swet realtors pvt. ltd. 1.33 1.33 1.33 1.33 1.33
umesh kumar gupta 1.98 1.84 1.68 1.42 1.42
varun jain 1.33 1.33 1.20 1.20 1.20
madhusudhan gunda 1.28 1.32 1.18 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Godavari Drugs informs about newspaper publication14 Feb 2024, 4:37PM Godavari Drugs - Quaterly Results13 Feb 2024, 5:52PM Godavari Drugs - Quaterly Results13 Feb 2024, 5:52PM Godavari Drugs informs about trading window closure30 Dec 2023, 2:40PM Godavari Drugs informs about loss of share certificate28 Sep 2023, 2:47PM Godavari Drugs informs about loss of share certificate1 Sep 2023, 3:34PM Godavari Drugs informs about disclosure19 Jun 2023, 10:39AM Godavari Drugs informs about disclosure8 Jun 2023, 1:07PM Godavari Drugs - Quaterly Results14 Feb 2023, 1:04PM Godavari Drugs informs about disclosure23 Dec 2022, 3:24PM Godavari Drugs informs about disclosure22 Dec 2022, 11:40AM Godavari Drugs informs about disclosure21 Dec 2022, 3:25PM Godavari Drug informs about press release16 Dec 2022, 4:08PM Godavari Drugs informs about updates15 Dec 2022, 3:42PM Godavari Drugs informs about notice of postal ballot26 Nov 2022, 12:31PM Godavari Drugs informs about compliance certificate13 Oct 2022, 12:28PM Godavari Drugs informs about compliance certificate13 Oct 2022, 12:26PM Godavari Drugs informs about board meeting intimation4 Aug 2022, 1:12PM Godavari Drugs - Quaterly Results19 Apr 2022, 1:56PM Godavari Drugs - Quaterly Results19 Apr 2022, 1:56PM Godavari Drugs - Quaterly Results19 Apr 2022, 1:56PM Godavari Drugs informs about transmission of shares9 Mar 2022, 3:09PM Godavari Drugs - Quaterly Results14 Feb 2022, 12:33PM Godavari Drugs informs about board meeting7 Feb 2022, 3:38PM Godavari Drugs informs about disclosure30 Dec 2021, 4:44PM Godavari Drugs informs about trading window closure4 Oct 2021, 3:48PM Godavari Drugs informs about board meeting10 Jun 2021, 2:28PM Godavari Drugs submits compliance certificate21 Oct 2020, 10:59AM

Godavari Drugs Stock Price Analysis and Quick Research Report. Is Godavari Drugs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Godavari Drugs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Godavari Drugs cash from the operating activity was Rs 13.2171 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Godavari Drugs has a Debt to Equity ratio of 1.0727 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Godavari Drugs , the EPS growth was -27.8246762569271 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Godavari Drugs has OPM of 6.21501170244222 % which is a bad sign for profitability.
     
  • ROE: Godavari Drugs have a average ROE of 12.0091484981427 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Godavari Drugs is Rs 92.95. One can use valuation calculators of ticker to know if Godavari Drugs share price is undervalued or overvalued.
Last Updated on:
Brief about Godavari Drugs
X